Callan Family Office, LLC Neurocrine Biosciences Inc Transaction History
Callan Family Office, LLC
- $3.14 Trillion
- Q3 2025
A detailed history of Callan Family Office, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Callan Family Office, LLC holds 1,912 shares of NBIX stock, worth $276,972. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,912
Previous 2,270
15.77%
Holding current value
$276,972
Previous $285 Million
5.93%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
724Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...